Disc Medicine (NASDAQ:IRON) Posts Earnings Results, Misses Estimates By $0.03 EPS

Disc Medicine (NASDAQ:IRON) announced its quarterly earnings results on Tuesday. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03), FiscalAI reports.

Disc Medicine Stock Down 1.6%

IRON stock traded down $1.12 during midday trading on Thursday, hitting $67.53. The company’s stock had a trading volume of 395,188 shares, compared to its average volume of 606,288. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 21.94. Disc Medicine has a twelve month low of $40.00 and a twelve month high of $99.50. The company’s fifty day moving average price is $65.01 and its 200 day moving average price is $76.09. The stock has a market capitalization of $2.58 billion, a P/E ratio of -10.20 and a beta of 0.93.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Cantor Fitzgerald cut their price objective on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Wells Fargo & Company boosted their price objective on shares of Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Stifel Nicolaus cut their price objective on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $104.80.

Insider Transactions at Disc Medicine

In other Disc Medicine news, COO Jonathan Yen-Wen Yu sold 3,231 shares of Disc Medicine stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $203,100.66. Following the sale, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $3,414,806.64. The trade was a 5.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Pamela Stephenson sold 5,531 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $347,678.66. Following the transaction, the insider owned 80,998 shares in the company, valued at $5,091,534.28. This represents a 6.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 59,410 shares of company stock worth $3,840,013. 3.64% of the stock is owned by insiders.

Institutional Investors Weigh In On Disc Medicine

A number of large investors have recently added to or reduced their stakes in IRON. RA Capital Management L.P. boosted its position in Disc Medicine by 25.3% during the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock worth $156,925,000 after purchasing an additional 399,026 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Disc Medicine by 28.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock valued at $134,839,000 after buying an additional 371,576 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Disc Medicine by 110.0% in the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after buying an additional 828,248 shares during the last quarter. Wellington Management Group LLP grew its stake in Disc Medicine by 7.7% in the 4th quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company’s stock valued at $120,566,000 after buying an additional 108,197 shares during the last quarter. Finally, State Street Corp grew its stake in Disc Medicine by 13.6% in the 4th quarter. State Street Corp now owns 1,187,991 shares of the company’s stock valued at $94,338,000 after buying an additional 142,394 shares during the last quarter. Institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.